Literature DB >> 6143974

Longitudinal study of persistent generalised lymphadenopathy in homosexual men: relation to acquired immunodeficiency syndrome.

U Mathur-Wagh, R W Enlow, I Spigland, R J Winchester, H S Sacks, E Rorat, S R Yancovitz, M J Klein, D C William, D Mildvan.   

Abstract

42 homosexual or bisexual men with persistent generalised lymphadenopathy not attributable to an identifiable cause have been followed longitudinally since February, 1981. Lymphadenopathy was accompanied by fatigue, low-grade fever and/or night sweats (57%), splenomegaly (29%), leucopenia (40%), hypergamma - globulinaemia (76%), and diminished proportion and absolute numbers of helper T cells (95%). Of the 26 patients who had lymph node biopsy, all showed benign reactive hyperplasia. After 15-30 (median 22) months, 8 patients have met criteria for the diagnosis of acquired immunodeficiency syndrome (AIDS). This outcome was associated with previous heavy nitrite inhalant use, with the presence of night sweats, with leucopenia, and with the triad of constitutional symptoms, splenomegaly, and leucopenia. In addition, a lower mean absolute helper T cell count and an increased frequency of anergy to mumps intradermal antigen and of herpes simplex virus isolation distinguished these patients from those remaining in the cohort, who seem to be stable and in some cases to have improved.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Americas; Behavior; Developed Countries; Developing Countries; Diseases; Hiv Infections; Homosexuals; Longitudinal Studies; North America; Northern America; Sex Behavior; United States; Viral Diseases

Mesh:

Substances:

Year:  1984        PMID: 6143974     DOI: 10.1016/s0140-6736(84)91449-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  The natural history of human T lymphotropic virus-III infection: the cause of AIDS.

Authors:  M Melbye
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

Review 2.  The clinical prognosis of HIV-1 infection: a review of 32 follow-up studies.

Authors:  G S Cooper; D J Jeffers
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

3.  Biopsy pathology of acquired immune deficiency syndrome (AIDS).

Authors:  A W Boylston; H T Cook; N D Francis; R D Goldin
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

4.  The histology of nasopharyngeal masses: a comparison between HIV positive and HIV negative patients.

Authors:  T Erasmus; T Daniller; J Goedhals; G Joubert; R Y Seedat
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-28       Impact factor: 2.503

5.  Abnormal antibody responses in patients with persistent generalized lymphadenopathy.

Authors:  H D Ochs; A K Junker; A C Collier; F S Virant; H H Handsfield; R J Wedgwood
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

6.  Defective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection.

Authors:  A Winkelstein; L A Kingsley; R S Klein; D W Lyter; T L Evans; C R Rinaldo; L D Weaver; L L Machen; R C Schadle
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

7.  Prognostic factors in acquired immunodeficiency syndrome.

Authors:  J D Wenger; C C Whalen; M M Lederman; T J Spech; J T Carey; J W Tomford; C S Landefeld
Journal:  J Gen Intern Med       Date:  1988 Sep-Oct       Impact factor: 5.128

Review 8.  Antiviral drugs for AIDS. Current status and future prospects.

Authors:  E Sandström
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

9.  The immunohistology of non-T cells in the acquired immunodeficiency syndrome.

Authors:  G S Wood; B F Burns; R F Dorfman; R A Warnke
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

10.  HBV, HDV and HIV infections in 242 drug addicts: two-year follow-up.

Authors:  C Mandelli; M Cesana; P Ferroni; G P Lorini; G P Aimo; A Tagger; P A Bianchi; D Conte
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.